-
EP3774921
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3774921
| EP3774921 - ANTIBODY VARIABLE DOMAINS TARGETING DLL3, AND USE THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.11.2022 Database last updated on 17.05.2024 | |
| Former | Request for examination was made Status updated on 15.01.2021 | ||
| Former | The international publication has been made Status updated on 12.10.2019 | Most recent event Tooltip | 18.11.2022 | Application deemed to be withdrawn | published on 21.12.2022 [2022/51] | Applicant(s) | For all designated states Dragonfly Therapeutics, Inc. 35 Gatehouse Drive Waltham, MA 02451 / US | [2021/07] | Inventor(s) | 01 /
BARUAH, Hemanta 2513 Navarro Trail Euless, TX 76039 / US | 02 /
CHEUNG, Ann, F. 25 Morningside Lane Lincoln, MA 01773 / US | 03 /
FALLON, Daniel 30 Stevens Street Winchester, MA 01890 / US | 04 /
GRINBERG, Asya 37 Follen Road Lexington, MA 02421 / US | 05 /
HANEY, William 61 Lincoln Road Wayland, MA 01778 / US | 06 /
O'NEIL, Steven 7 Pleasant Run Wayland, MA 01778 / US | [2021/07] | Representative(s) | Haseltine Lake Kempner LLP Cheapside House 138 Cheapside London EC2V 6BJ / GB | [N/P] |
| Former [2021/07] | Haseltine Lake Kempner LLP Cheapside House 138 Cheapside London EC2V 6BJ / GB | Application number, filing date | 19780584.9 | 03.04.2019 | [2021/07] | WO2019US25566 | Priority number, date | US201862651945P | 03.04.2018 Original published format: US 201862651945 P | [2021/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019195408 | Date: | 10.10.2019 | Language: | EN | [2019/41] | Type: | A1 Application with search report | No.: | EP3774921 | Date: | 17.02.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.10.2019 takes the place of the publication of the European patent application. | [2021/07] | Search report(s) | International search report - published on: | US | 10.10.2019 | (Supplementary) European search report - dispatched on: | EP | 07.12.2021 | Classification | IPC: | A61P35/00, C07K16/28 | [2022/01] | CPC: |
A61P35/00 (EP);
C07K16/28 (EP,US);
A61K38/2013 (EP);
A61K38/2026 (EP);
A61K38/2066 (EP);
A61K38/208 (EP);
C12N15/86 (US);
A61K31/40 (EP);
A61K31/5365 (EP);
A61K31/7034 (EP);
C07K2317/24 (EP,US);
C07K2317/31 (US);
C07K2317/33 (EP,US);
C07K2317/77 (EP,US);
C07K2317/92 (EP,US);
C07K2317/94 (EP,US)
(-)
| C-Set: |
A61K31/40, A61K2300/00 (EP);
A61K31/5365, A61K2300/00 (EP);
A61K31/7034, A61K2300/00 (EP)
|
| Former IPC [2021/07] | C07K16/28, A61K35/17, C12N15/86, A61K38/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/07] | Title | German: | ANTIKÖRPERVARIABLE DOMÄNEN GEGEN DLL3 UND VERWENDUNG DAVON | [2021/07] | English: | ANTIBODY VARIABLE DOMAINS TARGETING DLL3, AND USE THEREOF | [2021/07] | French: | DOMAINES VARIABLES D'ANTICORPS CIBLANT LES DLL3, ET LEUR UTILISATION | [2021/07] | Entry into regional phase | 15.10.2020 | National basic fee paid | 15.10.2020 | Search fee paid | 15.10.2020 | Designation fee(s) paid | 15.10.2020 | Examination fee paid | Examination procedure | 15.10.2020 | Examination requested [2021/07] | 21.05.2021 | Amendment by applicant (claims and/or description) | 14.07.2022 | Application deemed to be withdrawn, date of legal effect [2022/51] | 08.08.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/51] | Fees paid | Renewal fee | 27.04.2021 | Renewal fee patent year 03 | 27.04.2022 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2012125850 (AMGEN INC [US], et al) [Y] 5,6 * (p 20, l 8-9)(p 24, l 13-17) *; | [Y]EP2927321 (AJOU UNIV IND ACAD COOP FOUND [KR]) [Y] 5,6 * (table 1; fig 11) *; | [XI]WO2016179319 (CELLERANT THERAPEUTICS INC [US]) [X] 7-11 * claims 1,19,22,26,32,37,63 * [I] 12-16; | [XI]WO2017021349 (AMGEN RES (MUNICH) GMBH [DE]) [X] 7-11 * (p 2, para 1)(p 2-3, bridging para)(claims 25-27) *[I] 12-16; | [XI]WO2017201442 (ABBVIE STEMCENTRX LLC [US]) [X] 7-11 * abstract * [I] 3; | [XYI]US2018015178 (STULL ROBERT A [US], et al) [X] 2,4,7-11,17-19 * ([0184])([0006-7])(putative claims 25, 34)([0594][0593]putative claim 61;[0837]putative claims 11, 33;([0369])[0009])([0159])([0561]([0014]([0111]([0106]([0370]([0098]) * [Y] 5,6 [I] 1,3; | [Y] - ULRICH BRINKMANN ET AL, "The making of bispecific antibodies", MABS, US, (20170110), vol. 9, no. 2, doi:10.1080/19420862.2016.1268307, ISSN 1942-0862, pages 182 - 212, XP055531122 [Y] 5,6 * (p 191, col 2, last full para) * DOI: http://dx.doi.org/10.1080/19420862.2016.1268307 | International search | [A]WO2011075636 (AMGEN INC [US], et al) [A] 1-3, 16-18, 22-23, 58 * Claim 12; SEQ ID NO:112 *; | [A]WO2016028672 (MERCK SHARP & DOHME [US], et al) [A] 1-3, 16-18, 22-23 * Claim 1; SEQ ID NO:385 *; | [A]WO2017075432 (ALECTOR LLC [US]) [A] 58* Claim 27; SEQ ID NO:88 *; | [A]US2018044415 (ESCARPE PAUL ANTHONY [US], et al) [A] 58 * Abstract; Claim 1; Claim 2; Claim 3 * |